Meta and Mike Rowe launch $115 trade-training program that guarantees jobs to future welders, plumbers, electricians Ivar AI

Yahoo Entertainment

大股災！台股早盤崩跌2281點　台積電開盤價曝光

Elespanol.com

La tecnológica OpenAI solicita confidencialmente su salida a bolsa en Estados Unidos, sin fecha estimada para ello

Crypto Briefing

US Central Command intercepts Iranian missiles, strikes radar sites in Strait of Hormuz escalation

Xataka.com.mx

Dreame ya se convirtió en la pesadilla de Xiaomi donde su calidad-precio era insuperable: las aspiradoras robots

TechRadar

This Microsoft Defender zero-day could give hackers unprecedented access to your system

PBS

Exchange of missile strikes between Israel and Iran threatens fragile ceasefire

The Times of India

Citi leverages AI to transform payments, boost efficiency and enhance cross-border transactions

Marca

¿El peor en 100 años? Alerta en Colombia por la llegada de un Fenómeno de El Niño histórico

Diariobitcoin.com

Audiera ($BEAT) explota un 91% en 24 horas y supera los USD 4 el 8 de junio de 2026

Digitimes

AI demand is turning memory chips into rationed assets, Morgan Stanley says

The Times of India

Gulf countries act as propellants for SpaceX IPO as billions flow in

Foreign Policy

Trump Started a War He Can’t Control

Globo

Após Anthropic, OpenAI, do ChatGPT, entra com pedido de IPO nos EUA

Süddeutsche Zeitung

Israel: Israel und Iran greifen einander an

Noticiabrasil.net.br

Concessão de hidrovias destrava potencial logístico há décadas ignorado no Brasil, avaliam analistas

The Times of India

'The Donald of Dubai': UAE billionaire close to Trump bets $66 billion on AI to become the world's data king

Technews.tw

英特爾股價大漲！消息指 Alphabet 已下訂 300 萬顆晶片製造訂單

Forbes

Global AI Buildout Proves Wealth Lode For Its Picks-And-Shovels Billionaires In Taiwan

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire